These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 23580147

  • 1. Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification.
    Osako MK, Nakagami H, Shimamura M, Koriyama H, Nakagami F, Shimizu H, Miyake T, Yoshizumi M, Rakugi H, Morishita R.
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1287-96. PubMed ID: 23580147
    [Abstract] [Full Text] [Related]

  • 2. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
    Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B, Fernandez E, Valdivielso JM.
    Circ Res; 2009 May 08; 104(9):1041-8. PubMed ID: 19325147
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
    Min LJ, Mogi M, Iwanami J, Li JM, Sakata A, Fujita T, Tsukuda K, Iwai M, Horiuchi M.
    Cardiovasc Res; 2007 Dec 01; 76(3):506-16. PubMed ID: 17706954
    [Abstract] [Full Text] [Related]

  • 6. Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6.
    Callegari A, Coons ML, Ricks JL, Rosenfeld ME, Scatena M.
    J Vasc Res; 2014 Dec 01; 51(2):118-31. PubMed ID: 24642764
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    D'Amelio P, Isaia G, Isaia GC.
    J Endocrinol Invest; 2009 Dec 01; 32(4 Suppl):6-9. PubMed ID: 19724159
    [Abstract] [Full Text] [Related]

  • 9. The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification.
    Carrillo-López N, Martínez-Arias L, Alonso-Montes C, Martín-Carro B, Martín-Vírgala J, Ruiz-Ortega M, Fernández-Martín JL, Dusso AS, Rodriguez-García M, Naves-Díaz M, Cannata-Andía JB, Panizo S.
    Nephrol Dial Transplant; 2021 Mar 29; 36(4):618-631. PubMed ID: 33367746
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M, Matsuo K, Tada T, Fukushima H, Furuta H, Ozeki S, Kadowaki T, Yamamoto K, Okamoto M, Jimi E.
    Carcinogenesis; 2011 Nov 29; 32(11):1634-40. PubMed ID: 21890459
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension.
    Sendra J, Llorente-Cortés V, Costales P, Huesca-Gómez C, Badimon L.
    Cardiovasc Res; 2008 Jun 01; 78(3):581-9. PubMed ID: 18281370
    [Abstract] [Full Text] [Related]

  • 13. TLR2 Promotes Vascular Smooth Muscle Cell Chondrogenic Differentiation and Consequent Calcification via the Concerted Actions of Osteoprotegerin Suppression and IL-6-Mediated RANKL Induction.
    Lee GL, Yeh CC, Wu JY, Lin HC, Wang YF, Kuo YY, Hsieh YT, Hsu YJ, Kuo CC.
    Arterioscler Thromb Vasc Biol; 2019 Mar 01; 39(3):432-445. PubMed ID: 30626205
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells.
    Esteban V, Ruperez M, Sánchez-López E, Rodríguez-Vita J, Lorenzo O, Demaegdt H, Vanderheyden P, Egido J, Ruiz-Ortega M.
    Circ Res; 2005 May 13; 96(9):965-73. PubMed ID: 15831814
    [Abstract] [Full Text] [Related]

  • 15. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy.
    Ndip A, Williams A, Jude EB, Serracino-Inglott F, Richardson S, Smyth JV, Boulton AJ, Alexander MY.
    Diabetes; 2011 Aug 13; 60(8):2187-96. PubMed ID: 21659498
    [Abstract] [Full Text] [Related]

  • 16. Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification.
    Callegari A, Coons ML, Ricks JL, Yang HL, Gross TS, Huber P, Rosenfeld ME, Scatena M.
    Arterioscler Thromb Vasc Biol; 2013 Nov 13; 33(11):2491-500. PubMed ID: 23990207
    [Abstract] [Full Text] [Related]

  • 17. Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway.
    Zhan JK, Tan P, Wang YJ, Wang Y, He JY, Tang ZY, Huang W, Liu YS.
    Cardiovasc Diabetol; 2014 Nov 19; 13():153. PubMed ID: 25407893
    [Abstract] [Full Text] [Related]

  • 18. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells.
    Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M.
    Circ Res; 2005 Sep 02; 97(5):434-42. PubMed ID: 16081869
    [Abstract] [Full Text] [Related]

  • 19. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G.
    Expert Rev Cardiovasc Ther; 2006 Nov 02; 4(6):801-11. PubMed ID: 17173497
    [Abstract] [Full Text] [Related]

  • 20. Receptor activator of nuclear factor kappa B ligand/osteoprotegerin pathway is a promising target to reduce atherosclerotic plaque calcification.
    Quercioli A, Luciano Viviani G, Dallegri F, Mach F, Montecucco F.
    Crit Pathw Cardiol; 2010 Dec 02; 9(4):227-30. PubMed ID: 21119343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.